Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 4, 2010, Pages 1529-1534

  Scherer, Erin M ^a   Leaman, Daniel P ^b   Zwick, Michael B ^b   McMichael, Andrew J ^c   Burton, Dennis R ^b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

4E10; gp41; HIV; Neutralizing antibody; Tryptophan

Indexed keywords

LIPOSOME; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ARTICLE; CRYSTAL STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; BINDING SITES; CELL MEMBRANE; EPITOPES; HIV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HUMANS; IMMUNOGLOBULIN G; MEMBRANE LIPIDS; MOLECULAR SEQUENCE DATA;

EID: 76549125090     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909680107     Document Type: Article

References (50)

1. Mascola JR (2003) Defining the protective antibody response for HIV-1. Curr Mol Med 3:209-216.
2. Burton DR, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5:233-236.
3. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies froman African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
4. Binley JM, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232-13252.
5. Mehandru S, et al. (2004) Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 78:14039-14042.
6. Zwick MB, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905.
7. Nelson JD, et al. (2007) An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81:4033-4043.
8. Muster T, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
9. Zwick MB, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79:1252-1261.
10. Cardoso RM, et al. (2007) Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365:1533-1544.
11. Julien JP, Bryson S, Nieva JL, Pai EF (2008) Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: Epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 384:377-392.
12. Ofek G, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78:10724-10737.
13. Pejchal R, et al. (2009) A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83:8451-8462.
14. Cardoso RM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
15. Zwick MB (2005) The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring. AIDS 19:1725-1737.
16. Salzwedel K, West JT, Hunter E (1999) A conserved tryptophan-rich motif in the membrane proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 73:2469-2480.
17. Killian JA, von Heijne G (2000) How proteins adapt to a membrane-water interface. Trends Biochem Sci 25:429-434.
18. Suárez T, Nir S, Goñi FM, Saéz-Cirión A, Nieva JL (2000) The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: A novel fusogenic sequence. FEBS Lett 477:145-149.
19. Schibli DJ, Montelaro RC, Vogel HJ (2001) The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 40:9570-9578.
20. Song L, et al. (2009) Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci USA 106:9057-9062.
21. Sun ZY, et al. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
22. Grundner C, Mirzabekov T, Sodroski J, Wyatt R (2002) Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol 76:3511-3521.
23. Alam SM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178:4424-4435.
24. Huarte N, et al. (2008) The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol 82:8986-8996.
25. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
26. Sánchez-Martínez S, Lorizate M, Katinger H, Kunert R, Nieva JL (2006) Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 22:998-1006.
27. Scherer EM, Zwick MB, Teyton L, Burton DR (2007) Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139.
28. Vcelar B, et al. (2007) Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21:2161-2170.
29. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 1788:660-665.
30. Xu JL, Davis MM (2000) Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37-45.
31. Alving CR (2008) 4E10 and 2F5 monoclonal antibodies: Binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 22:649-651.
32. Zwick MB, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78:3155-3161.
33. Lorizate M, Gómara MJ, de la Torre BG, Andreu D, Nieva JL (2006) Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J Mol Biol 360:45-55.
34. White SH, Wimley WC (1998) Hydrophobic interactions of peptides with membrane interfaces. Biochim Biophys Acta 1376:339-352.
35. Barbas CF, 3rd, Burton DR, Scott JK, Silverman GJ (2001) Phage Display: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
36. Bebbington CR, et al. (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 10:169-175.
37. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
38. Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM (1988) Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci USA 85:900-904.
39. Aloia RC, Tian H, Jensen FC (1993) Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA 90:5181-5185.
40. Brügger B, et al. (2006) The HIV lipidome: A raft with an unusual composition. Proc Natl Acad Sci USA 103:2641-2646.
41. Richieri SP, et al. (1998) Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine 16:119-129.
42. Schlame M (2008) Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J Lipid Res 49:1607-1620.
43. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM(2005) Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies 14:59-67.
44. Montero M, van Houten NE, Wang X, Scott JK (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72:54-84.
45. Du J, Yang H, Guo Y, Ding J (2009) Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 46:2419-2423.
46. Parren PW, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75:8340-8347.
47. Buchacher A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10:359-369.
48. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 20:755-762.
49. Heckman KL, Pease LR (2007) Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2:924-932.
50. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100: 4144-4149.